Imbria – Optimizing cellular energy to treat cardiometabolic disorders

New treatments to enhance or restore how cells produce energy

View our Pipeline

Imbria Presented Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at ACC.24

Media Center

Results published in the Journal of the American College of Cardiology (JACC)

At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.

Developing new treatments for cardiometabolic disorders

Non-obstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200.

Stable angina

Chest pain from angina can feel like a heart attack. Stable angina affects more than 4% of the adult population and leads to significant reduction in quality of life.

Heart failure with preserved ejection fraction

Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs.

Latest news

Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24

ACC.24 Late-Breaking IMPROVE-HCM Presentation

April 08, 2024

Dr. Maron and Dr. Gibson Discuss Ninerafaxstat and IMPROVE-HCM

April 08, 2024

Journal of the American College of Cardiology

March 25, 2024

Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24)

View all news